Skip to main content
. Author manuscript; available in PMC: 2020 Nov 14.
Published in final edited form as: Leukemia. 2020 May 14;34(11):2981–2991. doi: 10.1038/s41375-020-0858-1

Figure 1. Culture in HS-5 CM protects FLT3-ITD+ AML cells from quizartinib.

Figure 1.

A. Apoptosis at 48 hours following treatment of various FLT3-ITD+ AML cell lines and the K562 cell line (negative control) with quizartinib 10 nM. Treated cells were cultured in medium conditions indicated by the blue, red and black bars. (n=3) B. Bar graphs comparing the IC50 values of quizartinib in FLT3-ITD+ AML cell lines cultured in RM or CM for 72 hours. (n=3) C. Primary CD34+ cells from AML patients with or without FLT3-ITD mutations were cultured in RM or CM and treated with graded concentrations of quizartinib in cell proliferation experiments (n=3)